TEKKA GROUP : Completion of tekka IPO on Alternext by NYSE Euronext Paris €11.25m raised Price set at €10.85 per share

Not for distribution directly or indirectly in the United States, Canada, Australia or Japan

8 February 2011
www.tekka.com

Completion of IPO on Alternext by NYSE Euronext Paris €11.25m raised Price set at €10.85 per share

tekka (FR0010999425, ALTKA), which designs, manufactures and sells innovative medical devices for use in Cranio-Maxillofacial Surgery, Orthodontics and Dental Implants, today announces the completion of its Initial Public Offering on Alternext by NYSE Euronext Paris and the raising of around €11.25 million from investors.
The price applicable to the Global Placement and the Open Price Offering has been set at €10.85 per share, below the indicative range initially proposed for the IPO of between €13.15 and €15.15 per share.
The number of new shares issued by the Company within the framework of the IPO is 1,036,867, it being specified that the maximum number of shares initially planned was 1,140,684. The option to extend the offer and the overallotment option will not be exercised.
The 1,036,867 shares subscribed are allocated as follows:
- Global Placement: 836,783 shares allocated to institutional investors;
- Open Price Offering: 200,084 shares allocated to retail investors.
Based on the price of €10.85 per share, the Company's market capitalisation stands at €43.25 million after the IPO.
The funds raised will enable the Company to implement its expansion plans and give it the financial means to:
- Develop new products in order to add to its existing product ranges;
- Offer a new set of personalised solutions based on bespoke manufacturing technology;
- Internalize part of its production facilities;
- Continue with its international expansion strategy by opening new subsidiaries and enlarging its distribution network; and
- Strengthen its cash position.
As the amount raised was lower than stated in the Prospectus (i.e. €15 million excluding the 15% extension option), the Company is planning to set up a new timetable for its international expansion, opening new subsidiaries on a more gradual basis.

1/3

Not for distribution directly or indirectly in the United States, Canada, Australia or Japan

After the IPO, the Company's share capital will be made up of 3,986,212 shares (after the conversion into ordinary shares of all securities giving indirect access to its share capital, apart from existing warrants). Its share capital will break down as follows:

Shares and voting rights Shares and voting rights after conversion of all after conversion of all 2009 mandatory 2009 mandatory convertible securities, convertible securities, 2009 convertible bonds & 2009 convertible bonds & 2010 convertible bonds 2010 convertible bonds and before exercise of and after exercise of Shareholders stock warrants stock warrants Number % Number % Thierry ROTA 845,630 21.2% 845,630 20.7% Karine ROTA 5 0.0% 5 0.0% ALPHATEK 565,965 14.2% 627,745 15.4%

Sub-total ROTA family 1,411,600 35.4% 1,473,380 36.1%

Benoit RODRIGUEZ 229,135 5.7% 229,135 5.6% Romeo CASIMIRO 2,585 0.1% 32,330 0.8% Thierry TURBANT 2,155 0.1% 2,155 0.1% Clémence BANCHET 1,725 0.0% 1,725 0.0% Jana RODRIGUEZ 860 0.0% 860 0.0% Sophie PERRIER 1,725 0.0% 1,725 0.0% Bernard CHAPOTAT 2,585 0.1% 2,585 0.1%

Sub-total other natural persons 240,770 6.0% 270,515 6.6%

Seventure Partners 5 0.0% 5 0.0% FCPI CAAM 6 166,865 4.2% 166,865 4.1% FCPI CAAM INNOVATION 7 49,290 1.2% 49,290 1.2% FCPI CAAM INNOVATION 8 123,240 3.1% 123,240 3.0% FCPI BANQUE POPULAIRE INNOVATION 9 190,700 4.8% 190,700 4.7% FCPI BANQUE POPULAIRE INNOVATION 10 238,380 6.0% 238,380 5.8% FCPI BANQUE POPULAIRE INNOVATION 11 115,025 2.9% 115,025 2.8% FCPI BANQUE POPULAIRE INNOVATION 12 123,245 3.1% 123,245 3.0%

Sub-total SEVENTURE PARTNERS 1,006,750 25.3% 1,006,750 24.7%

FCPI SELECT INNOVATION 5 139,345 3.5% 139,345 3.4% FCPI SELECT INNOVATION 6 85,495 2.1% 85,495 2.1% FIP SELECT EST 5 9,190 0.2% 9,190 0.2% FIP SELECT EST 6 56,195 1.4% 56,195 1.4%

Sub-total CM-CIC CAPITAL PRIVE 290,225 7.3% 290,225 7.1%

Public 1,036,867 26.0% 1,036,867 25.4%

Total 3,986,212 100.0% 4,077,737 100.0%

Settlement and delivery of the shares will take place on 11 February 2011 and trading will begin on 14
February 2011.
The shares will be traded on Alternext by NYSE Euronext Paris under the ISIN code FR0010999425 and the ticker ALTKA.

2/3

Not for distribution directly or indirectly in the United States, Canada, Australia or Japan

Thierry Rota, Founder and CEO of tekka, comments: "We are very pleased with the completion of this offering. We would like to thank all our new shareholders, as well as our partners and staff, who have chosen to put their trust in us and to accompany us through our development. Thanks to the funds raised, we expect to be able to accelerate our development in France and internationally, extend our product and service range, consolidate our leading position in the dental implants market and also increase our visibility."

ƒ Financial intermediary:

Global Coordinator, Bookrunner and Listing Sponsor: Bryan, Garnier & Co

ƒ Availability of the prospectus:

Copies of the prospectus, which includes the "document de base" registered on 18 January 2011 under number I.11-002 by the Autorité des Marchés Financiers (French securities market authority) and the "note d'opération" registered on 27 January 2011 under visa number 11-026, are available free of charge and on request from tekka, Direction Administrative et Financière, ZI de Sacuny - BP82, 118, avenue Marcel Mérieux - 69530 Brignais, France, or Bryan, Garnier & Co, 26 avenue des Champs-Elysées - 75008 Paris, France, as well as on the Autorité des Marchés Financiers website (www.amf-france.org) and the tekka website (www.tekka.com).

ƒ Risk factors:

The public's attention is drawn to the section entitled "Risk factors" in the Registration Document ("document de base") registered with the Autorité des Marchés Financiers. Further information about these risk factors is provided in chapter 4 of the "document de base" and Section 2 of the "note d'opération".

This press release does not and shall not in any circumstances constitute a public offering nor an invitation to the public in connection with any offer of financial securities.

The distribution of this press release in certain countries may constitute a violation of applicable laws. The information contained in this press release does not constitute an offer of securities in the United States, Canada, Australia, Japan or any other country. This press release may not be published, transferred or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

This document does not constitute an offer to sell tekka shares in the United States. tekka shares may not be sold in the United States without registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. tekka does not intend to register all or part of the offering referred to in this

document in the United States or make any public offering of shares in the United States.

ƒ Tax declarations

In order to allow retail investors to benefit, if applicable, from the facility to reduce their income or wealth tax liability, in respect of subscribing to new shares, the Company undertakes to meet the conditions of paragraph 2 of I of article 199 terdecies-0-A of the French General Tax Code (concerning reductions in income tax) and paragraphs a to g of 1 of Article 885-0 V bis of the French General Tax Code (concerning reductions in wealth tax), subject to the limits set by law and applicable regulations.

3/3

Not for distribution directly or indirectly in the United States, Canada, Australia or Japan

Contacts tekka NewCap. Press relations Financial communication and investor relations

Nathalie Genestoux Axelle Vuillermet / Julien Brosillon

Tel.: [phone] Tel.: [phone] [e-mail] [e-mail]

About tekka (www.tekka.com)

Established in 2000, tekka designs, manufactures and sells innovative medical devices for Cranio-Maxillo-Facial

Surgery, Orthodontics and Dental Implants. Thanks to its disruptive approach based on an original sales strategy, an attractive price positioning and unparalleled service standards, tekka has taken only five years to establish itself as France's No. 1 specialist in Cranio-Maxillofacial Surgery and No. 2 in Dental Implants (based on volumes)(1).

tekka - ZI de Sacuny - 118, av Marcel Mérieux - 69530 Brignais - France - www.tekka.com

(1) Source : Company

• Name: TEKKA GROUP

• ISIN Code: FR0010999425

• Ticker: ALTKA

4/3